| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
Biochemical markers of bone quality following administration of different pharmacological agents were measured in a rabbit hyperhomocysteinemia model(an experimental model of reduced human bone quality) developed in our laboratory. The results clearly indicated, similarly to our previously reported findings on human reduced-bone-quality-type osteoporosis that by incurring direct detrimental changes on collagen coss-links homocysteine reduces bone strength ; this mechanism is independent of reduction in bone density.
Additionally, based on findings that estrogen receptor modulators are more effective in patients with reduced-bone-quality-type osteoporosis, we suggest subdividing patients accordingly with the type of osteoporosis upon diagnosis and treatment of the disease.
|
